Incyte Corporation (INCY) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2025)
INCY's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
INCY Revenue Analysis (2014–2025)
As of March 2, 2026, Incyte Corporation (INCY) generated trailing twelve-month (TTM) revenue of $5.14 billion, reflecting exceptional growth of +27.8% year-over-year. The most recent quarter (Q4 2025) recorded $1.51 billion in revenue, up 10.3% sequentially.
Looking at the longer-term picture, INCY's 5-year compound annual growth rate (CAGR) stands at +14.0%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $5.14 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows INCY's business is primarily driven by J A K A F I (71%), OPZELURA (14%), and Milestone And Contract Revenue (3%). With over half of revenue concentrated in J A K A F I, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including GMAB (+21.0% YoY), EXEL (+9.9% YoY), and IBRX (+1026.0% YoY), INCY has underperformed the peer group in terms of revenue growth. Compare INCY vs GMAB →
Peer Comparison
Compare INCY's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| INCYCurrent | $5.1B | +27.8% | +14.0% | 26.1% | |
| GMAB | $21.5B | +21.0% | +32.0% | 31.1% | |
| EXEL | $2.3B | +9.9% | +18.6% | 37.6% | |
| IBRX | $15M | +1026.0% | +221.4% | -2334.2% | |
| MRUS | $35M | +55.9% | +4.7% | -753.0% | |
| CGON | $1M | +217.8% | - | -10067.3% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $5.14B | +21.2% | $4.70B | 91.5% | $1.34B | 26.1% |
| 2024 | $4.24B | +14.8% | $3.86B | 91.1% | $80.1M | 1.9% |
| 2023 | $3.70B | +8.9% | $3.38B | 91.5% | $651.8M | 17.6% |
| 2022 | $3.39B | +13.7% | $3.14B | 92.5% | $599.6M | 17.7% |
| 2021 | $2.99B | +12.0% | $2.80B | 93.7% | $637.5M | 21.3% |
| 2020 | $2.67B | +23.5% | $2.51B | 93.9% | $-240,291,000 | -9.0% |
| 2019 | $2.16B | +14.7% | $2.01B | 93.2% | $421.7M | 19.5% |
| 2018 | $1.88B | +22.5% | $1.75B | 93.2% | $155.4M | 8.3% |
| 2017 | $1.54B | +38.9% | $1.43B | 92.8% | $-235,683,000 | -15.3% |
| 2016 | $1.11B | +46.7% | $1.00B | 90.6% | $164.0M | 14.8% |
See INCY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs INCY Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare INCY vs AGIO
See how INCY stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is INCY's revenue growth accelerating or slowing?
INCY revenue is accelerating at +27.8% year-over-year, exceeding the 5-year CAGR of +14.0%. TTM revenue reached $5.1B. Growth momentum has increased versus prior periods.
What is INCY's long-term revenue growth rate?
Incyte Corporation's 5-year revenue CAGR of +14.0% reflects the sustained expansion pattern. Current YoY growth of +27.8% is above this long-term average.
How is INCY's revenue distributed by segment?
INCY reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.